mediator of acute inflammation | | |
mediator of chronic inflammation | | |
cell type: source for the chronic inflammation mediator TNF alpha | | |
Primary Effect of TNF alpha in chronic inflammation: | | |
may slow bone damage associated with rheumatoid arthritis | | |
reduces pharmacological activity of spironolactone, competes with penicillin G. for renal tubular secretion;inhibits probenecid uricosuric effect | | |
celecoxib | | |
salicylate, but less effective than aspirin as cyclooxygenase inhibitors | | |
transaminitis (increase serum aminotransferase) | | |
infusion of this drug: accelerates closure of patent ductus arteriosus in premature newborns | | |